Peter OConnell
Overview
Explore the profile of Peter OConnell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernandez-Garcia R, Walsh D, OConnell P, Passero L, de Jesus J, Laurenti M, et al.
Mol Pharm
. 2025 Feb;
22(3):1437-1448.
PMID: 39960049
The incidence of visceral leishmaniasis (VL) remains a significant health threat in endemic countries. Fixed-dose combination (FDC) of amphotericin B (AmB) and miltefosine (MLT) is a promising strategy for treating...
2.
Chen J, Kang J, Yuan S, OConnell P, Zhang Z, Wang L, et al.
Pharmaceuticals (Basel)
. 2024 Apr;
17(4).
PMID: 38675376
The use of herbal medicine as an adjuvant therapy in the management of gastric cancer has yielded encouraging outcomes, notably in enhancing overall survival rates and extending periods of disease...
3.
Fernandez-Garcia R, Walsh D, OConnell P, Slowing K, Raposo R, Ballesteros M, et al.
Eur J Pharm Biopharm
. 2023 Jan;
183:74-91.
PMID: 36623752
The incidence and prevalence of invasive fungal infections have increased significantly over the last few years, leading to a global health problem due to the lack of effective treatments. Amphotericin...
4.
Gonzalez-Gonzalez O, Ramirez I, Ramirez B, OConnell P, Ballesteros M, Torrado J, et al.
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36365143
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), along with the World Health Organization (WHO), has provided a set of guidelines (ICH Q1A-E, Q3A-B,...
5.
Focaroli S, Jiang G, OConnell P, Fahy J, Healy A
Pharmaceutics
. 2020 Nov;
12(11).
PMID: 33233520
The aim of this study was to investigate the use of a three-fluid atomising nozzle in a lab-scale spray dryer for the production of dry powders intended for pulmonary delivery....
6.
Mah P, OConnell P, Focaroli S, Lundy R, OMahony T, Hastedt J, et al.
Eur J Pharm Biopharm
. 2019 Sep;
144:139-153.
PMID: 31536784
Trehalose is commonly used as a protein stabilizer in spray dried protein formulations delivered via the pulmonary route. Spray dried trehalose formulations are highly hygroscopic, which makes them prone to...
7.
Walsh D, Serrano D, Worku Z, Madi A, OConnell P, Twamley B, et al.
Int J Pharm
. 2018 Sep;
551(1-2):241-256.
PMID: 30223079
The comparison of spray drying versus hot melt extrusion (HME) in order to formulate amorphous solid dispersions has been widely studied. However, to the best of our knowledge, the use...
8.
Serrano D, Walsh D, OConnell P, Mugheirbi N, Worku Z, Bolas-Fernandez F, et al.
Eur J Pharm Biopharm
. 2017 Dec;
124:13-27.
PMID: 29196273
Engineering of pharmaceutical cocrystals is an advantageous alternative to salt formation for improving the aqueous solubility of hydrophobic drugs. Although, spray drying is a well-established scale-up technique in the production...
9.
Mugheirbi N, OConnell P, Serrano D, Healy A, Taylor L, Tajber L
Mol Pharm
. 2017 Sep;
14(11):3718-3728.
PMID: 28922604
Fluid bed coating offers potential advantages as a formulation platform for amorphous solid dispersions (ASDs) of poorly soluble drugs, being a one-step manufacturing process which could reduce the risk of...
10.
Worku Z, Kumar D, Gomes J, He Y, Glennon B, Ramisetty K, et al.
Int J Pharm
. 2017 Aug;
531(1):191-204.
PMID: 28801109
The development of solid dosage forms and manufacturing processes are governed by complex physical properties of the powder and the type of pharmaceutical unit operation the manufacturing processes employs. Suitable...